Pourhassan explains the difference between this emergency investigational new drug (IND) circumstance versus its ongoing Phase 1b/2 clinical trial on leronlimab.
Full interview: CytoDyn injects first breast cancer patient with its flagship therapy
Quick facts: CytoDyn
Market Cap: $162.01 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE